Home » FDA Holds Meeting for Leronlimab Rationale, Dosing in CCR5+ MSS mCRC

FDA Holds Meeting for Leronlimab Rationale, Dosing in CCR5+ MSS mCRC

by Roman Fabbricatore | Aug 14, 2024 | Articles | 0 Comments